Eric Coldwell
Stock Analyst at Baird
(3.91)
# 708
Out of 4,435 analysts
105
Total ratings
55.42%
Success rate
7.65%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON PLC | Maintains: Outperform | $363 → $367 | $324.82 | +12.99% | 11 | May 31, 2024 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $45 → $36 | $25.39 | +41.79% | 2 | May 14, 2024 | |
| CRL Charles River Laboratories International | Maintains: Outperform | $282 → $270 | $208.44 | +29.53% | 6 | May 10, 2024 | |
| PINC Premier | Maintains: Neutral | $25 → $22 | $18.92 | +16.28% | 4 | May 8, 2024 | |
| MCK McKesson | Maintains: Outperform | $603 → $671 | $569.59 | +17.80% | 9 | May 8, 2024 | |
| OMI Owens & Minor | Maintains: Neutral | $28 → $24 | $17.43 | +37.69% | 9 | May 6, 2024 | |
| IQV IQVIA Holdings | Maintains: Neutral | $254 → $245 | $219.09 | +11.83% | 8 | May 3, 2024 | |
| CAH Cardinal Health | Maintains: Outperform | $134 → $128 | $99.27 | +28.94% | 8 | May 3, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $255 → $244 | $194.91 | +25.19% | 7 | Apr 26, 2024 | |
| MEDP Medpace Holdings | Maintains: Outperform | $446 → $454 | $386.34 | +17.51% | 9 | Apr 24, 2024 | |
| CTLT Catalent | Upgrades: Outperform | $45 → $53 | $53.79 | -1.47% | 1 | Nov 16, 2023 | |
| AHCO AdaptHealth | Maintains: Outperform | $20 → $21 | $9.48 | +121.52% | 8 | Jul 13, 2023 | |
| DGX Quest Diagnostics | Maintains: Neutral | $143 → $154 | $141.97 | +8.47% | 2 | Jan 12, 2023 | |
| WBA Walgreens Boots Alliance | Downgrades: Neutral | $51 | $16.22 | +214.43% | 15 | Apr 1, 2022 | |
| FUL H.B. Fuller Company | Maintains: Neutral | n/a | $79.63 | - | 1 | Mar 27, 2020 | |
| CVS CVS Health | Maintains: Neutral | n/a | $59.60 | - | 3 | Mar 27, 2020 | |
| INCR InterCure | Maintains: Outperform | n/a | $2.95 | - | 2 | Nov 10, 2017 |
ICON PLC
May 31, 2024
Maintains: Outperform
Price Target: $363 → $367
Current: $324.82
Upside: +12.99%
Fortrea Holdings
May 14, 2024
Upgrades: Outperform
Price Target: $45 → $36
Current: $25.39
Upside: +41.79%
Charles River Laboratories International
May 10, 2024
Maintains: Outperform
Price Target: $282 → $270
Current: $208.44
Upside: +29.53%
Premier
May 8, 2024
Maintains: Neutral
Price Target: $25 → $22
Current: $18.92
Upside: +16.28%
McKesson
May 8, 2024
Maintains: Outperform
Price Target: $603 → $671
Current: $569.59
Upside: +17.80%
Owens & Minor
May 6, 2024
Maintains: Neutral
Price Target: $28 → $24
Current: $17.43
Upside: +37.69%
IQVIA Holdings
May 3, 2024
Maintains: Neutral
Price Target: $254 → $245
Current: $219.09
Upside: +11.83%
Cardinal Health
May 3, 2024
Maintains: Outperform
Price Target: $134 → $128
Current: $99.27
Upside: +28.94%
Labcorp Holdings
Apr 26, 2024
Maintains: Outperform
Price Target: $255 → $244
Current: $194.91
Upside: +25.19%
Medpace Holdings
Apr 24, 2024
Maintains: Outperform
Price Target: $446 → $454
Current: $386.34
Upside: +17.51%
Catalent
Nov 16, 2023
Upgrades: Outperform
Price Target: $45 → $53
Current: $53.79
Upside: -1.47%
AdaptHealth
Jul 13, 2023
Maintains: Outperform
Price Target: $20 → $21
Current: $9.48
Upside: +121.52%
Quest Diagnostics
Jan 12, 2023
Maintains: Neutral
Price Target: $143 → $154
Current: $141.97
Upside: +8.47%
Walgreens Boots Alliance
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $16.22
Upside: +214.43%
H.B. Fuller Company
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $79.63
Upside: -
CVS Health
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $59.60
Upside: -
InterCure
Nov 10, 2017
Maintains: Outperform
Price Target: n/a
Current: $2.95
Upside: -